 |
|
|
 |
AHRQ Recommendations And Reports: Aspirin For The Primary Prevention Of Cardiovascular
Events
As promised to our readers, Vidyya is pleased to post this report, from the AHRQ, about aspirin for
the prevention of cardiovascular events. According to the AHRQ, aspirin can prevent myocardial infarctions but increases the
risk of gastrointestinal bleeding and appears to increase the risk of hemorrhagic stroke. The net benefit of aspirin increases with
increasing cardiovascular risk. The decision about whether to use aspirin chemoprevention requires consideration of the patient's
cardiovascular risk as well as the patient's relative utility for the different clinical outcomes prevented or caused by its use.
more
|
|
Heavy Backpacks Linked To Back Pain In Kids
Carrying backpacks--typically weighing 20 pounds or more--is an important contributor to back pain
in schoolchildren, reports a study in the January issue of the journal Spine. more
|
|
|
|
Study Questions Work-Related Risk Factors For Spinal Disc Degeneration
The risk of disc degeneration in the lower back is not necessary related to back pain, nor to the
occupational risk factors--such as heavy lifting--traditionally associated with back pain, reports a study in the January issue of
the journal Spine. more
|
|
Physicians Often Mislead Terminal Patients; Education Needed To Help Physicians Deal With Delivering
Difficult News
According to an article in the current issue of the American Journal of Hospice & Palliative Care by
Matt Stolick, PhD, physicians, generally speaking, lie to dying patients, resulting in the patient not knowing that he or she will die
until the last 30 days of so of the patient's life. more
|
|
FDA Approves Use Of Pathvysion Breast Cancer Test To Select Appropriate Candidates For
Herceptin Therapy
The Vysis PathVysion HER-2 DNA Probe Kit to detect the HER-2/neu gene in breast cancer patients
received approval from the US Food and Drug Administration (FDA) for use in identifying women with metastatic breast cancer
who could benefit from Herceptin therapy late last week. more
|
|
|
